Welcome to our dedicated page for Genelux Corporation news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux Corporation stock.
Genelux Corporation (NASDAQ: GNLX) is a clinical-stage biopharmaceutical company dedicated to developing advanced oncolytic viral immunotherapies. The company focuses on innovative treatments for aggressive and difficult-to-treat solid tumors. At the forefront of their pipeline is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus. Olvi-Vec is currently being evaluated in a Phase 3 registrational trial, OnPrime/GOG-3076, which aims to assess its efficacy and safety in combination with platinum-doublet and bevacizumab for patients with platinum-resistant/refractory ovarian cancer.
Genelux leverages its proprietary CHOICE™ platform to develop a range of oncolytic vaccinia virus immunotherapeutic products. This platform has enabled the company to create an extensive library of product candidates designed to harness the body's immune system to combat cancer.
In recent news, Genelux announced its fourth-quarter and full-year financial results for 2023, showcasing significant progress and strategic business updates. The company is also in the process of a public offering, with Guggenheim Securities and Newbridge Securities Corporation acting as the sole book-running manager and co-manager, respectively.
The offering is backed by an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC), and the proceeds are expected to support general corporate purposes through the first quarter of 2026. Genelux emphasizes transparency and regulatory compliance, ensuring potential investors have access to detailed prospectus supplements via the SEC's website.
Genelux continues to advance its mission of transforming cancer treatment through innovative viral therapies while maintaining a solid financial and strategic foundation. For more detailed information and updates on their projects and financial health, investors and stakeholders are encouraged to stay tuned to their official announcements and regulatory filings.
Genelux (NASDAQ: GNLX) has announced the dosing of the first patient in its U.S.-based Phase 2 (VIRO-25) trial. This trial aims to evaluate the efficacy and safety of systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.
The VIRO-25 trial (NCT06463665) is an open-label, randomized study comparing Olvi-Vec followed by platinum-doublet chemotherapy + Physician's Choice of ICI to docetaxel. This marks the second indication for Olvi-Vec via systemic administration in the clinic. Genelux expects an interim data readout in mid-2025.
The company's CEO, Thomas Zindrick, emphasized the significance of this milestone for NSCLC patients with therapeutic options. This trial, along with an ongoing Phase 1b/2 trial in recurrent small cell lung cancer, positions Olvi-Vec as a potential systemically administered oncolytic virus treatment option.
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event is scheduled to take place from October 15-17, 2024.
Thomas Zindrick, President, CEO, and Chairman of the Board of Genelux, will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim. The discussion is set for October 15, 2024, at 2:00 pm E.T.
During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This presentation offers an opportunity for investors and interested parties to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024, in New York City. Thomas Zindrick, President, Chairman and CEO, will engage in a fireside chat with Emily Bodnar, Vice President of Equity Research and H.C. Wainwright Biotechnology Analyst, on September 11 at 12:30 p.m. ET.
The presentation will cover Genelux's clinical-stage programs, recent announcements, and upcoming milestones. A webcast of the event will be available, with an archived replay accessible for approximately 90 days on the company's IR page. Genelux will also participate in virtual one-on-one meetings during the conference, offering institutional investors the opportunity to engage directly with management.
Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell lung cancer later this year. The ongoing Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer continues enrollment with topline results expected in H2 2025.
Financial highlights include:
- Cash, cash equivalents, and investments of $40.4 million as of June 30, 2024
- R&D expenses increased to $4.4 million in Q2 2024
- G&A expenses remained flat at $2.5 million
- Net loss of $6.6 million or $0.22 per share
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in BTIG's Virtual Biotechnology Conference 2024. The company's President, CEO, and Chairman, Thomas Zindrick, will engage in a fireside chat with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst. The discussion is scheduled for Tuesday, August 6, 2024, at 12:00 p.m. ET.
During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This event presents an opportunity for investors and industry professionals to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.
Genelux (Nasdaq: GNLX), an immuno-oncology company, has announced the pricing of an underwritten offering of 6,875,000 shares of common stock and accompanying warrants at $4.00 per share and warrant. Each warrant will have an exercise price of $5.25. The gross proceeds are expected to be approximately $27.5 million, with net proceeds providing working capital into Q1 2026. The funds will support the clinical development of Olvi-Vec, with Phase 3 trial results anticipated in H2 2025. The offering is expected to close around May 29, 2024. Guggenheim Securities and Newbridge Securities are managing the offering. A 30-day option for an additional 1,031,250 shares and warrants is also included.
Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.
The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.
Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.
FAQ
What is the current stock price of Genelux Corporation (GNLX)?
What is the market cap of Genelux Corporation (GNLX)?
What does Genelux Corporation specialize in?
What is Olvi-Vec?
What is CHOICE™ platform?
What is the current status of the OnPrime/GOG-3076 trial?
Who are the managers for Genelux's public offering?
How can I access the prospectus for the public offering?
What are the expected use of proceeds from the public offering?
Where is Genelux Corporation headquartered?
What recent financial results has Genelux reported?
How can I get more information about Genelux?
